863971-29-3

Upstream product

• 863971-41-9 (2R,3R)-3-{(2S)-1-[(9H-fluoren-9-ylmethoxy)carbonyl]pyrrolidin-2-yl}-3-methoxy-2-methylpropanoic acid 
• 69610-41-9 Boc-L-Pro-H 
• 159173-40-7 (2S,1'R,2'S)-N-(tert-butoxycarbonyl)-2-(1'-hydroxy-2'-methyl-3'-butenyl)-pyrrolidine 
• 159173-43-0 (2S,1'R,2'S)-N-(tert-butoxycarbonyl)-2-(1'-methoxy-2'-methyl-3'-butenyl)-pyrrolidine 
• 120205-50-7 N-Boc-(2R,3R,4S)-dolaproine 
• 75898-47-4 phenylalanine t-butyl ester hydrochloride salt 
• 109-89-7 diethylamine 

Relevant academic research and scientific papers

Preparation method of drug-linker MC-MMAF for antibody drug conjugate and intermediate thereof

The invention provides a preparation method of a drug-linker MC-MMAF for antibody coupling drugs and an intermediate thereof. According to the preparation method of the drug-linker MC-MMAF, the reaction activity of the N end is improved, the occurrence of racemization reaction is effectively controlled; toxin MMAF is not directly used, a fragment peptide with lower toxicity is adopted, the operation difficulty in mass production is reduced, no reverse phase preparation is needed, and the operation is simple and convenient.

Monomethylvaline compounds conjugated with antibodies

Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF

The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.

CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF

The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.